Clearmind Medicine Inc. CMND

NeuroThera Labs Inc. (TSXV: NTLX) and Clearmind Medicine Inc. report three U.S. patent applications covering novel combos of LSD, ketamine, and ibogaine with NeuroThera's N-acylethanolamine (PEA) technology. The filings target potential therapies for mental health disorders (depression, PTSD), pain, and substance-use disorders, expanding on prior IP that includes MDMA plus N-acylethanolamines. The partners say the expanded portfolio demonstrates broader applications of PEA technology with psychedelic compounds and aims to support development of safer, more effective neuropsychiatric treatments. The news follows ongoing collaboration to advance such programs toward market, while acknowledging risks including patent grants, safety/efficacy in trials, and financing needs. Broader patent coverage and ongoing collaboration expand the potential therapeutic scope and IP moat around the NeuroThera-Clearmind programs, potentially boosting CMND's value and strategic partnerships.

Clearmind Medicine announced the U.S. publication of three patent applications for proprietary combinations of LSD, ketamine and ibogaine with N-acylethanolamines (e.g., palmitoylethanolamide, PEA). The filings, developed with NeuroThera Labs, cover potential therapeutic uses across mental health disorders (depression, PTSD), pain and substance-use disorders, expanding a portfolio that Clearmind says includes 19 patent families and 32 granted patents. The company aims to deliver non-hallucinogenic, neuroplastogen-based therapies and argues that combining psychedelics with PEA could enable lower, potentially better-tolerated doses. Clearmind notes ongoing collaboration with NeuroThera and previously announced a U.S. patent on MDMA with N-acylethanolamines. CEO Adi Zuloff-Shani says the move aligns with growing interest in these compounds and could improve tolerability while preserving efficacy. The company trades on Nasdaq under the symbol CMND. Strengthens IP moat and collaboration potential, with long-term upside contingent on patent issuance and clinical results.

Three U.S. patent applications have been published covering combinations of LSD, ketamine, and ibogaine with NeuroThera's palmitoylethanolamide (PEA) technology, as part of a collaboration with Clearmind Medicine and SciSparc's NeuroThera Labs. The filings target potential treatments for depression, PTSD, pain, and substance-use disorders, building on earlier patents for MDMA with N-acylethanolamines. The move expands NeuroThera's IP portfolio and could broaden the therapeutic potential of psychedelic-assisted approaches. While the filings signal longer-term value, success depends on clinical data, regulatory approval, and commercialization. Expansion of CMND's IP through collaboration could bolster long-term value but near-term impact is uncertain.

Clearmind Medicine briefed the FDA after invitation to a historic psychedelic hearing in Washington, D.C. FDA briefing after historic hearing invitation advances Clearmind's regulatory standing in psychedelic treatments.

Clearmind Medicine Inc. has enrolled the first patients with alcohol use disorder in its CMND-100 clinical trial. Initial patient enrollment in CMND-100 advances Clearmind's alcohol use disorder treatment program but remains an early-stage milestone.

Clearmind Medicine received Yale IRB approval to recruit patients for parts B and C of its CMND-100 Phase I/II trial following positive safety results. Yale IRB approval advances CMND-100 trial to next stages after positive safety data, strengthening development prospects.

Clearmind Medicine Inc. (CMND) agrees to acquire 51% stake in Charging Robotics for $2.5 million. Acquisition of majority stake in Charging Robotics marks a significant strategic expansion that could alter Clearmind Medicine's trajectory.

Clearmind Medicine Inc. (CMND) has started CMND-100 Phase IIa trial for Alcohol Use Disorder with one-third of Part C enrolled. Phase IIa trial start and enrollment advance CMND's lead drug candidate toward potential regulatory and commercial milestones.

Clearmind Medicine advances MDMA-N-acylethanolamines IP for PTSD treatment via NeuroThera collaboration amid rising U.S. federal support for psychedelic innovation. IP advancement in PTSD treatment with federal backing positions Clearmind for major strategic gains and investor interest.

Clearmind Medicine Inc. advances MDMA-N-acylethanolamines IP for PTSD treatment amid rising U.S. federal support for psychedelic innovation. IP advancement for PTSD in federally backed psychedelic sector signals major positive trajectory shift for Clearmind.

Clearmind Medicine Inc. advanced CMND-100 to Alcohol Use Disorder patients after achieving the primary safety endpoint. Advancement of CMND-100 after safety milestone marks key clinical progress that can shift company trajectory and sentiment.

Clearmind Medicine reported positive permeation results for its intranasal MEAI formulation, showing enhanced nasal retention without compromising drug delivery. Positive permeation data supports progress on Clearmind's intranasal MEAI formulation but remains an early development step.

Clearmind Medicine advances its AUD clinical trial after DSMB unanimously clears progression following review of key milestone data. Unanimous DSMB clearance de-risks the lead AUD program and supports further development toward potential regulatory steps.

Clearmind Medicine Inc. signs letter of intent to acquire 51% majority stake in EV wireless charging solutions for automated parking systems company. Majority stake acquisition signals major strategic move into unrelated EV sector that could alter company trajectory.

Clearmind Medicine Inc. (CMND) announced positive safety findings for CMND-100, showing consistent tolerability throughout full dose escalation in Part A of its FDA-regulated clinical trial. Positive safety data from completed dose escalation supports clinical advancement and may lift investor sentiment for CMND.

Clearmind Medicine Inc. successfully completes Part A of its FDA regulated Phase I/II trial. Trial completion marks major regulatory milestone advancing core drug development pipeline.

Clearmind Medicine files Hong Kong patent for novel psychedelic compounds, expanding global IP portfolio and targeting multi-billion-dollar PTSD therapeutics market. Patent filing adds IP protection in large PTSD market but remains early-stage without immediate revenue or approval impact.

Clearmind Medicine supports federal efforts advancing psychedelic-based therapies for mental health and addiction treatment. Federal momentum on psychedelic therapies signals regulatory tailwinds likely to boost Clearmind Medicine's market position and investor outlook.

Clearmind Medicine reports positive retention results for intranasal formulation of its psychedelic-based neuroplastogen MEAI. Positive retention data on intranasal MEAI advances product formulation progress for Clearmind Medicine.

Clearmind Medicine reports promising real-world insights from its ongoing first-in-human CMND-100 trial. Positive early-stage trial data can materially advance pipeline progress and lift investor sentiment for the company.

Clearmind Medicine Inc. secures new U.S. patent, strengthening global IP portfolio. New patent grant supports ongoing innovation and IP protection for Clearmind Medicine.

Clearmind Medicine Inc. completed Part A treatment in its FDA-regulated Phase I/II clinical trial. Advancing through Part A of an FDA Phase I/II trial marks major clinical progress that can significantly lift company trajectory and investor sentiment.

Clearmind Medicine Inc. (CMND) was granted a U.S. patent for binge behavior regulators. Patent grant secures intellectual property for Clearmind Medicine's core technology potentially enhancing market position.

Clearmind Medicine Inc. completes dosing for Part A of its FDA-regulated Phase I/II clinical trial. Dosing completion in Phase I/II trial advances drug development pipeline.

Clearmind Medicine Inc. (CMND) stock surged 40% in a single trading session. A 40% single-day stock surge signals major positive developments likely to drive substantial shifts in valuation and investor interest.

Clearmind Medicine files Japanese patent for psychedelic-based depression treatment, expanding global IP portfolio. Patent filing in Japan bolsters IP protection for core depression treatment but does not alter near-term operations or revenue.

Clearmind Medicine secures Johns Hopkins IRB approval to advance CMND-100 Phase I/II clinical trial to next parts. IRB approval advances CMND-100 trial progression, likely strengthening development timeline and investor sentiment.

Clearmind Medicine expands obesity therapy strategy via new Tirzepatide combination study to enhance treatment options. Tirzepatide study directly advances Clearmind's core obesity pipeline and competitive stance in a high-growth market.

Clearmind Medicine Inc. signed agreement to examine MEAI in combination and sequencing with Tirzepatide against blockbuster GLP-1 medications. Early-stage research pact on drug combinations may support pipeline progress without immediate major commercial effects.

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. CEO's delegate role at federal psychedelic policy summit elevates company's visibility and potential influence in regulatory discussions.